HK Innoen plans to appeal soon in connection with the loss of the first trial of the new drug "K-Cap" for gastroesophageal reflux disease, a blockbuster item.
"We will submit an appeal to the Patent Court in defiance of the first trial decision on the K-cap decision patent," an HK Innoen official said in a telephone interview with WikiLeaks Korea on the 11th. "We are considering future countermeasures such as filing a complaint with the Patent Court after reviewing the trial decision in detail."
He added, "We are also submitting a mutual opinion regarding the material patent invalidation trial filed with the Patent Tribunal by Generic companies."
Previously, more than 60 domestic pharmaceutical companies, including Daemi Pharmaceutical and Samcheondang Pharmaceutical, recently won some of the K-Cap passive scope confirmation trials filed with the Patent Tribunal.
K-Cap has three major patents.
These include crystalline patents and use patents that expire in 2036, and material patents that expire in 2031.
In the lawsuit, Hae-hae Pharmaceutical and Samcheondang Pharmaceutical won some of the decisive patents that expire in 2036.
K-CAB, a new P-CAB family treatment for gastroesophageal reflux disease, is the domestic new drug No. 30 K-CAB. Since its launch in 2019, it has recorded growth every year, boasting annual sales of more than 100 billion won.
Until last year, the cumulative prescription alone recorded 508.5 billion won.
As it is literally a blockbuster product, the highest-ever patent war is expected to take place following HK Innoen's appeal.
[WIKI KOREA=Cho Eun, Reporter]
choeun@wikileaks-kr.org
